Furberg, Full Drug Safety Committee To Be Present At COX-2 Meeting
Executive Summary
Wake Forest University epidemiologist Curt Furberg will participate with FDA's full Drug Safety & Risk Management Advisory Committee in the upcoming review of the COX-2 inhibitor therapeutic class
You may also be interested in...
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
SMART-er Isotretinoin Risk Management Program To Be Operated By Covance
Covance will develop and operate a single, enhanced risk management program for all four isotretinoin products
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011